Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-18

Study Completion Date

2025-02-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 2, multicenter, randomized, double-blind, parallel group, 2 arm study in approximately 40 subjects aged 4 to 50 years, inclusive, who are allergic to cow's milk. The primary objective is to assess whether dupilumab as an adjunct to milk oral immunotherapy (OIT) compared to placebo improves the safety of milk OIT and rates of desensitization, defined as an increase in the proportion of subjects who pass a double-blind placebo-controlled food challenge (DBPCFC) to at least 2040 mg cumulative milk protein at week 18.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Baked Milk Oral Immunotherapy for Cow's Milk Allergy

NCT03462030

Cow's Milk Allergy

COMPLETED PHASE2

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

NCT03679676

Hypersensitivity Food Allergy Hypersensitivity, Food +2 more

COMPLETED PHASE2

OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

NCT01157117

Milk Allergy

COMPLETED PHASE2

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

NCT03682770

Peanut Allergy

COMPLETED PHASE2

Expanded Access Program of Dupilumab in Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Who Have Been Previously Treated With Linvoseltamab and Background Dupilumab in the Parent Study R5458-668-ALG-2219 (NCT06369467)

NCT06631677

Food Allergy

NO_LONGER_AVAILABLE

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergies Food Milk

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

dupilumab or placebo arm

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dupilumab

24-week treatment period, which includes a 4-week run-in period with dupilumab followed by 12 weeks of treatment with dupilumab in combination with a gradual up-dosing of milk protein OIT, then followed by 8 weeks of milk OIT dosing with no dupilumab

Group Type EXPERIMENTAL

Dupilumab

Intervention Type DRUG

Dupilumab injected every 2 weeks for 18 weeks

Placebo

24-week treatment period, which includes a 4-week run-in period with placebo for dupilumab followed by 12 weeks of treatment with placebo for dupilumab in combination with a gradual up-dosing of milk protein OIT, then followed by 8 weeks of milk OIT dosing with no placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo injected every 2 weeks for 18 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dupilumab

Dupilumab injected every 2 weeks for 18 weeks

Intervention Type DRUG

Placebo

Placebo injected every 2 weeks for 18 weeks

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 4 to 50 years (inclusive)
* Clinical history of allergy to cow's milk or milk-containing foods
* Serum IgE to milk of \>4 kUA/L within the last 12 months and/or a SPT to milk ≥6 mm compared to a negative control
* Experience clinical reaction at or before 444 mg cumulative protein dose of cow's milk protein on Screening DBPCFC
* No clinical reaction observed during the placebo (oat) Screening DBPCFC
* Subjects with other known food allergies must agree to eliminate these other food items from their diet so as not to confound the safety and efficacy data from the study
* Use of effective birth control by female participants of childbearing potential

Exclusion Criteria

* Any previous exposure to dupilumab
* Known hypersensitivity to dupilumab or any of its excipients
* Known hypersensitivity to epinephrine or any of its excipients
* Allergy to oat (placebo in DBPCFC)
* History of severe anaphylaxis to cow's milk, defined as neurological compromise or requiring intubation
* Recent history of frequent severe, life-threatening episodes of anaphylaxis or anaphylactic shock as defined as 3 or more episodes of anaphylaxis within the past year
* Inability to tolerate biological (antibody) therapies
* Body weight \<5 kg at the time of screening
* History of eosinophilic esophagitis (EoE), other eosinophilic gastrointestinal disease, chronic, recurrent, or severe gastroesophageal reflux disease (GERD), symptoms of dysphagia (e.g., difficulty swallowing, food "getting stuck"), or recurrent gastrointestinal symptoms of undiagnosed etiology
* History of cardiovascular disease, including uncontrolled or inadequately controlled hypertension
* History of a mast cell disorder
* Established diagnosis of a primary immunodeficiency disorder
* Severe asthma or mild or moderate asthma if uncontrolled or difficult to control
* Current participation or within the last 4 months in any other interventional study
* Use of medication such as beta-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers
* Pregnant or breastfeeding women

Minimum Eligible Age

4 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No